Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.
Lebron MB, Brennan L, Damoci CB, Prewett MC, O'Mahony M, Duignan IJ, Credille KM, DeLigio JT, Starodubtseva M, Amatulli M, Zhang Y, Schwartz KD, Burtrum D, Balderes P, Persaud K, Surguladze D, Loizos N, Paz K, Kotanides H. Lebron MB, et al. Among authors: balderes p. Cancer Biol Ther. 2014 Sep;15(9):1208-18. doi: 10.4161/cbt.29523. Epub 2014 Jun 12. Cancer Biol Ther. 2014. PMID: 24921944 Free PMC article.
Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.
Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, Zhu Z. Lu D, et al. Among authors: balderes p. J Biol Chem. 2004 Jan 23;279(4):2856-65. doi: 10.1074/jbc.M310132200. Epub 2003 Oct 23. J Biol Chem. 2004. PMID: 14576153 Free article.
Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E, Deevi DS, Balderes P, Bassi R, Jimenez X, Joynes CJ, Mangalampalli VR, Steiner P, Tonra JR, Wu Y, Pereira DS, Zhu Z, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Kussie P. Loizos N, et al. Among authors: balderes p. Mol Cancer Ther. 2005 Mar;4(3):369-79. doi: 10.1158/1535-7163.MCT-04-0114. Mol Cancer Ther. 2005. PMID: 15767546
Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL, Pereira DS. O'Toole JM, et al. Among authors: balderes p. Cancer Res. 2006 Sep 15;66(18):9162-70. doi: 10.1158/0008-5472.CAN-06-0283. Cancer Res. 2006. PMID: 16982759
An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.
Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D, Jimenez X, Iacolina M, Bassi R, Zhou K, Balderes P, Mangalampalli VR, Loizos N, Ludwig DL, Zhu Z. Shen J, et al. Among authors: balderes p. Biochem Biophys Res Commun. 2007 Jun 15;357(4):1142-7. doi: 10.1016/j.bbrc.2007.04.075. Epub 2007 Apr 19. Biochem Biophys Res Commun. 2007. PMID: 17462601
Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.
Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, Bassi R, Persaud K, Rohoza-Asandi A, Balderes P, Loizos N, Ludwig DL, Tonra J, Witte L, Zhu Z. Shen J, et al. Among authors: balderes p. Neoplasia. 2009 Jun;11(6):594-604. doi: 10.1593/neo.09278. Neoplasia. 2009. PMID: 19484148 Free PMC article.
Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y. Zhong Z, et al. Among authors: balderes p. Clin Cancer Res. 2010 Feb 15;16(4):1191-205. doi: 10.1158/1078-0432.CCR-09-1634. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145179
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.
Shen Y, Zeng L, Novosyadlyy R, Forest A, Zhu A, Korytko A, Zhang H, Eastman SW, Topper M, Hindi S, Covino N, Persaud K, Kang Y, Burtrum D, Surguladze D, Prewett M, Chintharlapalli S, Wroblewski VJ, Shen J, Balderes P, Zhu Z, Snavely M, Ludwig DL. Shen Y, et al. Among authors: balderes p. MAbs. 2015;7(5):931-45. doi: 10.1080/19420862.2015.1055442. MAbs. 2015. PMID: 26073904 Free PMC article.
Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity.
Shen Y, Zeng L, Zhu A, Blanc T, Patel D, Pennello A, Bari A, Ng S, Persaud K, Kang YK, Balderes P, Surguladze D, Hindi S, Zhou Q, Ludwig DL, Snavely M. Shen Y, et al. Among authors: balderes p. MAbs. 2013 May-Jun;5(3):418-31. doi: 10.4161/mabs.24291. Epub 2013 Apr 8. MAbs. 2013. PMID: 23567210 Free PMC article.
28 results